{"pub": "wsj", "url": "https://barrons.com/articles/abbvie-stock-is-slumping-but-vice-chairman-laura-schumacher-bought-shares-51568977221?mod=rsswn", "downloaded_at": "2019-09-20 13:00:49.591872+00:00", "title": "AbbVie Stock Is Falling Because Investors Hate the Allergan Deal. The Vice Chairman Bought Up Shares.", "language": "en", "text": "Text size\n\nAbbVie stock has crumbled to a two-and-a-half-year low in 2019, but the biopharmaceutical company\u2019s vice chairman has loaded up on the shares.\n\nAbbVie (ticker: ABBV) sported a 22.3% loss for the year to date through Thursday\u2019s close, compared with the 19.9% rise in the S&P 500.\n\nInvestors don\u2019t like AbbVie\u2019s June agreement to buy Allergan (AGN), and they don\u2019t get a say in the matter, either. Insiders have been snapping up AbbVie stock, but the price remains depressed.\n\nAbbVie stock slipped to $62.66 on Aug. 16, its lowest intraday level since March 2017.\n\nEditor's Choice\n\nLaura Schumacher, AbbVie\u2019s vice chairman, made her first open-market purchase of AbbVie stock on Sept. 16, paying $1.76 million for 25,000 shares, an average per-share price of $70.42. She now owns 164,838 shares, mostly acquired through stock awards and options, according to a form Schumacher filed with the Securities and Exchange Commission.\n\nAbbVie declined to make Schumacher available for comment on her purchase.\n\nSchumacher has been with AbbVie since it was spun off from Abbott Laboratories (ABT) in 2013. She had been a top executive at Abbott since 2005.\n\nInside Scoop is a regular Barron\u2019s feature covering stock transactions by corporate executives and board members\u2014so-called insiders\u2014as well as large shareholders, politicians, and other prominent figures. Due to their insider status, these investors are required to disclose stock trades with the Securities and Exchange Commission or other regulatory groups.\n\nWrite to Ed Lin at edward.lin@barrons.com and follow @BarronsEdLin.", "description": "Schumacher made her first open-market purchase of stock, paying $1.8 million for shares of the biopharmaceutical firm.", "authors": ["Ed Lin"], "top_image": "https://images.barrons.com/im-86109/social", "published_at": "2019-09-20"}